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Adipocyte Differentiation-Related Protein and OXPAT
in Rat and Human Skeletal Muscle: Involvement in
Lipid Accumulation and Type 2 Diabetes Mellitus
Ronnie Minnaard, Patrick Schrauwen, Gert Schaart, Johanna A. Jorgensen,
Ellen Lenaers, Marco Mensink, and Matthijs K.C. Hesselink
NUTRIM School for Nutrition, Toxicology, and Metabolism (R.M., P.S., G.S., J.A.J., E.L., M.K.C.H.),
Departments of Human Movement Sciences and Human Biology, Maastricht University Medical
Centre, 6200 MD Maastricht, The Netherlands; and Wageningen University (M.M.), Division of Human
Nutrition, 6700 EV Wageningen, The Netherlands
Setting: A disordered lipid metabolism is implicated in the development of skeletal muscle insulin
resistance. Lipid droplet proteins of the PAT [perilipin, adipocyte differentiation-related protein
(ADRP), and TIP47] family have been shown to regulate lipid accumulation and intracellular me-
tabolism in other tissues.
Objective: This study aimed to explore the role of the PAT proteins OXPAT and ADRP in skeletal
muscle lipid metabolism and their putative role in modulating insulin sensitivity.
Design: Muscle OXPAT and ADRP protein content was examined during the development of insulin
resistance in Zucker diabetic fatty (ZDF) rats and in type 2 diabetes patients and BMI-matched
control subjects. Furthermore, we examined the effect of 8 wk of insulin sensitizing by rosiglita-
zone on muscle OXPAT and ADRP content.
Results: OXPAT and ADRP protein expression is muscle fiber type specific in humans and rats, with
highest protein content in fibers containing most intramyocellular lipids (IMCL). Muscle OXPAT and
ADRP protein content was 2- to 3-fold higher in ZDF rats during the progression of type 2 diabetes
than in lean normoglycemic control rats, which was paralleled by high IMCL levels. Muscle OXPAT
and ADRP content, as well as IMCL level, was not different between type 2 diabetes patients and
control subjects. ADRP content was negatively associated with insulin-stimulated glucose uptake
(r  0.50; P  0.017). Interestingly, rosiglitazone treatment decreased muscle OXPAT (29%) and
ADRP (28%) content in diabetes patients, without affecting IMCL.
Conclusions: These results indicate involvement of OXPAT and ADRP in muscular lipid accumula-
tion and type 2 diabetes. (J Clin Endocrinol Metab 94: 4077–4085, 2009)
Skeletal muscle insulin resistance plays a major role inthe pathogenesis of type 2 diabetes (T2D). Disor-
dered lipid metabolism is considered a major factor in
causing skeletal muscle insulin resistance. From studies in
nontrained humans (1–4) and insulin-resistant rodent
models (5–7), it is known that levels of im triacylglycerols
correlate negatively with insulin sensitivity. A growing
body of evidence, however, supports the notion that not
the triacylglycerols (TAGs) per se, but the accompanying
increase in lipid metabolites (like diacylglycerol, cer-
amides, and fatty-acyl coenzyme A) may cause skeletal
muscle insulin resistance (8).
TAGs are mainly stored in neutral lipid droplets, coated
by lipid droplet-associating proteins referred to as the PAT
family, named after perilipin, adipocyte differentiation-re-
lated protein (ADRP), and tail-interacting protein of 47 kDa
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(9).Twootherproteinsof thisPATfamilyhave recentlybeen
identified, i.e. OXPAT (also known as myocardial lipid
droplet protein or lipid storage droplet protein 5) and S3–12
(10–12). Perilipin is the most extensively studied member of
this family, and it exerts primary control over adipose tissue
TAG stores by regulating both TAG storage and lipolysis.
Perilipin is only expressed in adipose tissue, whereas the ex-
pression levels of the other four PAT proteins vary widely
across tissues. Although originally identified as an early
marker of adipocyte differentiation (13), ADRP is now
known to be expressed in a variety of tissues, including mus-
cle (14–17). Its expression is related to the total neutral lipid
mass in the cell (14, 18). Indeed, ADRP overexpression stim-
ulates fatty acid uptake and triacylglycerol formation in var-
ious cell types (19, 20). OXPAT is another PAT-family pro-
tein, which is mainly expressed in tissues with high fat
oxidative capacity, like heart, skeletal muscle, and brown
adipose tissue (11, 21, 22), and is recruited to lipid droplets
in conditions that promote lipid droplet formation (11). In
addition, a role for OXPAT in the regulation of fatty acid
oxidation was observed in vitro (11).
Given their tissue distribution, particularly OXPAT
and ADRP are interesting candidates to be involved in the
modulation of muscular lipid storage and degradation.
Little is known, however, about their exact role in skeletal
muscle lipid metabolism. OXPAT and ADRP have been
implicated in the regulation of both TAG storage and hy-
drolysis in the lipid droplet, two processes affecting the
level and type of lipid intermediates present. Because a
dysregulation of lipid metabolism, and especially the pres-
ence of these lipid intermediates, is implicated in the de-
velopment of skeletal muscle insulin resistance and T2D,
we here aimed to explore the role of OXPAT and ADRP
in the development of insulin resistance. For this purpose,
the muscle content of both proteins was determined dur-
ing the progression of insulin resistance in the Zucker di-
abetic fatty (ZDF) rat model, as well as in T2D patients
and body mass index (BMI)-matched control subjects. Be-
cause muscle is comprised of muscle fibers of distinct sub-
types that vary in fat oxidative and storage capacity, we
also examined muscle fiber type-specific expression of
OXPAT and ADRP. Finally, to examine whether OXPAT
and ADRP protein content are related to muscular insulin
sensitivity, we studied the effect of the thiazolidinedione
rosiglitazone—known to improve insulin sensitivity—on
muscular OXPAT and ADRP content in T2D patients.
Subjects and Methods
ZDF rat study design
Twenty-six male, leptin receptor-deficient ZDF rats (ZDF/
Gmi, fa/fa) and 26 heterozygous lean littermates (ZDF/Gmi,
fa/) were purchased from Charles River Laboratories, Inc.
(Wilmington, MA), and housed in pairs of one genotype, on a
12-h light, 12-h dark cycle (light from 0700 to 1900 h), at 21–22
C with ad libitum access to tap water and diet [16.7 energy
percentage (En%) fat, 56.4 En% carbohydrates, and 26.8 En%
protein; Purina 5008, Altromin, Lage, Germany].
Blood was sampled by orbital punction after 4 h of fasting. At
6, 12, and 19 wk of age (n  8, n  8, and n  10 per age and
genotype, respectively), rats were killed by cervical dislocation,
and muscles were dissected, rapidly frozen in melting 2-methyl
butane (Fluka, Zwijndrecht, The Netherlands), and stored at
80 C. Experiments were approved by the Institutional Animal
Care and Use Committee.
Human study design
Subjects
Thirteen middle-aged obese men with T2D and nine age- and
BMI-matched male control subjects participated in this study
(see Table 1 for characteristics). T2D was diagnosed at least 1 yr
before the study and was well controlled. Before the study, blood
glucose homeostasis was maintained using oral glucose lowering
medication in all but one subject; one patient was treated with
diet only, six with metformin, five with sulfonylurea, and one
with metformin and sulfonylurea. Control subjects had normal
glucose tolerance, as measured with an oral glucose tolerance
test, and had no family history of diabetes. In addition to their
antidiabetic medication, five of 13 patients were taking statins to
lower their cholesterol, two were taking angiotensin II receptor







Age (yr) 58.2  7.5 62.8  4.3
Body weight (kg) 92.8  14.1 91.3  13.1 92.6  13.3
BMI (kg/m2) 30.6  4.25 30.2  3.8 30.6  3.7
VO2max
(ml/kg  min)
33.0  5.1 29.7  6.2a
Total cholesterol
(mmol/liter)
5.3  1.1 5.1  0.5 5.1  0.8
LDL cholesterol
(mmol/liter)
3.4  1.0 3.4  0.4 3.4  0.7
HDL cholesterol
(mmol/liter)
1.1  0.4 1.1  0.2 1.2  0.2
Triglycerides
(mmol/liter)
1.1  0.4 1.3  0.5 1.2  0.5
Fasting glucose
(mmol/liter)
5.9  0.5 8.5  2.1b 7.9  1.9
Fasting insulin
(mU/liter)
12.8  2.2 18.6  11.2 14.3  5.3d
Free fatty acids
(mol/liter)
518  152 425  111 391  115
HbA1c (%) 7.0  0.7 7.3  1.3
M-value
(mol/kg  min)
24.3  8.0 20.5  8.2 25.3  7.3c
Rd-glucose
(mol/kg  min)
20.3  11.2 14.9  7.5 18.7  7.3
VO2max, Maximal oxygen uptake; HbA1c, glycosylated hemoglobin.
a P  0.05.
b P  0.01, T2D patients before rosiglitazone vs. control.
c P  0.05.
d P  0.01, T2D patients before vs. after rosiglitazone treatment.
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antagonists, and one was taking a -antagonist to control blood
pressure. This medication was maintained throughout the study
to avoid differential effects on pre- and posttreatment outcome
measures. The Institutional Medical Ethical Review Committee
approved the study protocol.
Design
Fourteen days before the trial, diabetic patients discontinued
their antidiabetic medication. Subjects refrained from any (ex-
haustive) physical activity 3 d preceding the measurements. After
baseline measurements, diabetic subjects received rosiglitazone
in the maximum licensed dose for T2D patients (2  4 mg/d) for
8 wk. To avoid effects of differences in dosage of rosiglitazone
used, we started using identical dosage for all subjects. Fasting
blood glucose was measured every 2 wk to allow dose readjust-
ments if required. At the end of this 8-wk period, all measure-
ments were repeated. Despite the variability in antidiabetic
medication before the study, all subjects maintained glucose
homeostasis well throughout the intervention period, and no
readjustments in rosiglitazone dosage had to be made. Control
subjects were measured once.
Hyperinsulinemic euglycemic clamp
A 3-h hyperinsulinemic euglycemic clamp was performed
with parallel infusion of [6,6-2H2]glucose, as described earlier
(23). Before the clamp, after an overnight fast, a muscle biopsy
was taken from the vastus lateralis muscle according to Bergstrom
et al. (24). Insulin-stimulated plasma glucose rate of disap-
pearance (Rd) was calculated using Steele’s single-pool non-
steady-state equations adapted for use with stable isotopes
because no isotopic or glycemic steady-state was present. Vol-
ume of distribution was assumed to be 0.160 liters/kg for
glucose.
Plasma assays
Blood was collected in EDTA-containing tubes, and plasma
was stored at 80 C. Plasma free fatty acids and glucose were
measured in human and rat plasma with enzymatic assays au-
tomated on a Cobas Fara/Mira (free fatty acids, Wako Nefa C
test kit; Wako Chemicals, Neuss, Germany; glucose, hexokinase
method; LaRoche, Basel, Switzerland). Total cholesterol (ABX
Diagnostics, Montpelier, France), high-density lipoprotein
(HDL) cholesterol (precipitation method; Roche Diagnostics
Corporation, Indianapolis, IN), and triglycerides corrected for
free glycerol (Sigma-Aldrich, Zwijndrecht, The Netherlands)
were analyzed enzymatically. Serum low-density lipoprotein
(LDL) cholesterol concentrations were calculated by using the
formula of Friedewald et al. (25). Plasma insulin concentration
was determined in humans using a RIA (Linco Research, St.
Charles, MO) and in rats using an ultrasensitive solid phase
two-site ELISA kit (Mercodia, Uppsala, Sweden). Isotopic en-
richment of human plasma glucose was determined by electron
ionization gas chromatography-mass spectrometry and expressed
as tracer–tracee ratio.
Muscle analyses
Muscle samples were homogenized in ice-cold PBS con-
taining 1% Nonidet-P40, 0.5% sodium dodecyl sulfate, 0.1
mM phenylmethylsulfonyl fluoride, complete inhibitor (Roche,
Almere, The Netherlands) and processed for standard SDS-
PAGE and Western blotting. Protein concentration was as-
sessed, and equal amounts of protein were loaded per lane.
Membranes were incubated with antibodies against OXPAT
(no. GP31, guinea pig polyclonal; Progen, Heidelberg, Ger-
many) and ADRP (no. RDI-PROGP40, guinea pig polyclonal;
Fitzgerald Industries RDI division, Concord, MA). The anti-
bodies used were tested on a variety of tissues known to vary
in OXPAT and ADRP content [white adipose tissue, cardiac
muscle, glycolytic skeletal muscle (extensor digitorum lon-
gus), oxidative skeletal muscle (soleus), liver tissue, and tes-
tis]. For both antibodies, bands corresponding to the antici-
pated molecular weight of the protein were identified. These
bands responded according to the expression profile previ-
ously described by others. Finally, we chose to load on each
blot a ZDF rat heart sample as a positive control for the OX-
PAT antibody and an oleate-incubated (800 M, 24 h) C2C12
muscle cell sample as a positive control for the ADRP anti-
body. Blots were probed with IRDye800-conjugated second-
ary antibodies (Rockland, Gilbertsville, PA), and bands at a
molecular weight corresponding to the control samples were
quantified using the Odyssey infrared imaging system (LICOR
Biosciences, Lincoln, NE).
Histology
Intramyocellular lipid (IMCL) was quantified in human sub-
jects using Oil Red O (ORO) staining combined with immuno-
fluorescence labeling of the basal membrane marker laminin and
myosin heavy chain type 1 (26). IMCL was expressed as area
fraction, computed by dividing the area covered by lipid droplets
by the cell surface of the measured muscle fibers.
Immunofluorescent staining of OXPAT and ADRP (both
1:50 in PBS) was performed in human muscle biopsies and rat
gastrocnemius muscles using the above-mentioned antibodies
combined with an Alexa488-conjugated secondary antibody
(1:200 in PBS; Molecular Probes, Invitrogen, Breda, The
Netherlands). Experiments omitting OXPAT/ADRP antibod-
ies yielded no signal. OXPAT and ADRP staining was per-
formed on cryosections combined with either ORO staining
or fiber typing, exactly as described in Ref. 26. Antibodies
against myosin heavy chain types 1 and 2a (A4.840 and
N2.261, Developmental Studies Hybridoma Bank, both 1:25
in PBS) were used for fiber typing and were combined with
Alexa555- and Alexa350-conjugated secondary antibodies,
respectively.
Statistics
Data are presented as mean  SD. Substrate fluxes are ex-
pressed as micromoles per kilogram per minute. Statistics were
performed using SPSS 13.0 for Windows (SPSS, Inc., Chicago,
IL). By performing a Kolmogorov-Smirnov test, a normal Gauss-
ian distribution was shown for all data examined. Hence, para-
metric testing was used to test the measured variables. Differ-
ences between groups were compared using an unpaired
Student’s t-test; the treatment effect of rosiglitazone was ana-
lyzed using a paired Student’s t-test. Correlation analysis was
performed using two-sided Pearson’s correlation analysis. Two-
way ANOVA was used to examine age, genotype, and
agegenotype interaction effects in the rat experiments. A Bon-
ferroni post hoc test was performed to compare time points
within genotypes. Statistical significance was set at P  0.05.











Body mass and food intake were significantly higher in
the fa/fa than in the fa/ rats (P  0.001 at all ages). Body
mass of the rats killed at 6 wk of age averaged 194  6 vs.
147  11 g (fa/fa vs. fa/; P  0.001); of the 12-wk-old
rats, 345  17 vs. 284  32 g (P  0.001); and of the
19-wk-old rats, 373  16 vs. 335  19 g (P  0.001).
Similar values are reported in literature for the ZDF
model (27).
Blood glucose levels were slightly, but significantly,
higher in fa/fa rats compared with fa/ rats at wk 6 (4.6 
0.2 vs. 3.9  0.3 mmol/liter; P  0.05) and rapidly in-
creased in the fa/fa rats toward wk 12 (13.5  1.3 mmol/
liter) and wk 19 (16.1  0.8 mmol/liter). Blood glucose
levels remained within the normoglycemic range in the
fa/ rats (3.8  0.4 and 4.0  0.7 mmol/liter at wk 12 and
19, respectively; P  0.05 vs. fa/fa). From wk 6 onward,
insulin levels in fa/fa rats were significantly higher than in
fa/ rats (1.6  0.9 vs. 0.2  0.0, 1.6  0.7 vs. 0.4  0.2,
and 0.8  0.2 vs. 0.3  0.1 g /liter at 6, 12, and 19 wk,
respectively; P  0.05 for each comparison). Both geno-
types showed similar and stable plasma free fatty acid
levels throughout the study (181  48 vs. 166  53, 180 
42 vs. 206  61, and 172  36 vs. 193  82 mol/liter,
at 6, 12, and 19 wk for fa/fa vs. fa/ rats, respectively).
ADRP and OXPAT in ZDF rats
OXPAT and ADRP protein is present in rat gastrocne-
mius muscle fibers in a punctate staining pattern (Fig. 1, A
and C, respectively). In rodents, OXPAT and ADRP ex-
pression was highest in type 2a muscle fibers, intermediate
in type 1 muscle fibers, and almost absent in type 2b fibers
(Fig. 1, B and D, respectively). This pattern corresponds
well with the IMCL content of these fibers. OXPAT pro-
tein content was not different between genotypes at 6 wk
of age [0.84  0.24 arbitrary units (AU) in fa/fa rats vs.
0.77  0.39 AU in fa/ rats; P  0.64; Fig. 2A], whereas
OXPAT content increased and was higher at 12 wk
(2.06  0.33 vs. 0.78  0.38 AU; P  0.001) and 19 wk
(1.36  0.35 vs. 0.43  0.19 AU; P  0.001) of age in fa/fa
compared with fa/ rats. Interestingly, muscular ADRP
content was already higher at 6 wk of age in fa/fa com-
pared with fa/ rats (1.35  0.35 vs. 0.83  0.22 AU,
respectively; P  0.01; Fig. 2B), and this difference re-
mained at 12 wk (1.42  0.34 vs. 0.61  0.11 AU; P 
0.001) and 19 wk (1.18  0.12 vs. 0.50  0.13 AU; P 
0.001) of age. In contrast with OXPAT, ADRP protein
content in fa/fa rats did not change significantly between
6 and 19 wk of age.
Human subjects
Subject characteristics are shown in Table 1. By defi-
nition, T2D patients had significantly higher fasting
plasma glucose levels (P  0.01) and a tendency toward
higher fasting plasma insulin levels (P  0.095) compared
with control subjects. Plasma HDL cholesterol tended to
increase in T2D patients upon rosiglitazone treatment
(pretreatment, 1.11  0.2 mmol/liter, vs. posttreatment,
1.20  0.2 mmol/liter; P  0.06). Other lipoprotein-re-
lated parameters (total cholesterol, LDL cholesterol, and
circulatory triglycerides) were comparable between T2D
and BMI-matched controls and were not significantly af-
fected by rosiglitazone treatment (Table 1).
Insulin sensitivity and substrate oxidation
Insulin-stimulated glucose uptake (Rd) was 27% lower
in T2D patients compared with obese controls, but this did
not reach significance (14.9  7.5 vs. 20.3  11.2 mol/
kg  min; P  0.19). Rosiglitazone treatment tended to
increase insulin-stimulated glucose uptake almost to con-
trol levels in T2D patients (14.9  7.5 to 18.7  7.3 mol/
kg  min; P  0.089).
FIG. 1. OXPAT and ADRP immunofluorescent staining on ZDF rat
gastrocnemius muscle sections. A, Combined OXPAT (green) and
ORO (red) staining showing higher OXPAT levels in fibers containing
much lipid. The basal membrane marker laminin is stained blue. B,
Fiber-typing performed on serial sections (corresponding to panel
A). Type 1 fibers are red, type 2a fibers are green, and type 2b
fibers are unstained. C, Combined ADRP (green) and ORO (red)
staining showing high ADRP levels in fibers containing much lipid.
D, Fiber-typing on serial sections (corresponding to panel C). Images
are shown for a ZDF rat aged 12 wk, but stainings performed on
two ZDF and two control rats of each age group show similar
staining patterns.
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Muscle biopsy analyses
In humans, OXPAT and ADRP content was highest in
muscle fibers with the most abundant storage of IMCL
(Fig. 3, A and C), i.e. type 1 fibers (Fig. 3, B and D).
Colocalization of OXPAT with lipid droplets in the mus-
cle fibers is apparent in Fig. 3A. OXPAT and ADRP con-
tent were similar in T2D patients and controls (OXPAT,
1.28  0.68 vs. 1.16  0.62 AU, P  0.67; ADRP, 0.65 
0.40 vs. 0.63  0.29 AU, P  0.88, in T2D patients vs.
controls, respectively; Fig. 4). IMCL levels were not dif-
ferent between T2D patients and age- and BMI-matched
controls at baseline (7.1  2.9 and 6.7  2.2%, respec-
tively; P  0.74; Fig. 4E), which matches with the lack of
difference in OXPAT and ADRP content. Interestingly,
rosiglitazone treatment decreased the muscle content of
both OXPAT (1.28  0.68 to 0.91  0.65 AU; P  0.05;
Fig. 4, A and B) and ADRP (0.65  0.40 to 0.47  0.25
AU; P  0.05; Fig. 4, C and D), whereas IMCL content was
not affected by rosiglitazone treatment (7.1  3.1 to 8.3 
3.2%; P  0.22). Moreover, no differences in IMCL con-
tent were observed between groups or after rosiglitazone
when analyzed for each fiber type separately (Fig. 4E).
Correlations
In humans, skeletal muscle ADRP protein content cor-
related negatively with insulin-stimulated glucose uptake
in all subjects (Fig. 5; r  0.50; P  0.02). This corre-
lation approached significance in the separate groups
(T2D patients before, r  0.51, P  0.08; controls, r 
0.60, P  0.09). OXPAT protein content did not cor-
relate with insulin sensitivity. Rosiglitazone-induced
changes in ADRP and OXPAT protein content did not
correlate.
Discussion
We show that OXPAT and ADRP are expressed in human
and rat skeletal muscle and that their expression is fiber-
type specific, with highest protein content in muscle fibers
that contain most IMCL. Moreover, muscular OXPAT
and ADRP protein content was much higher in ZDF rats
FIG. 2. OXPAT (A) and ADRP (B) protein content in gastrocnemius
muscle of 6-, 12-, and 19-wk-old ZDF rats (fa/fa) and lean control rats
(fa/). *, P  0.05 fa/fa vs. fa/. Brackets indicate significant
differences between age groups within the genotypes.
FIG. 3. OXPAT and ADRP immunofluorescent staining on muscle
sections from a T2D patient. A, Combined OXPAT (green) and ORO
(red) staining showing higher OXPAT levels in fibers containing much
lipid. B, OXPAT staining combined with fiber-typing. Type 1 fibers are
red, type 2a fibers blue, and type 2b fibers unstained. C, Combined
ADRP (green) and ORO (red) staining showing high ADRP levels in
fibers containing much lipid. D, ADRP staining combined with fiber-
typing. E, Combined OXPAT (green) and ADRP (red) staining showing
that both proteins colocalize to a large degree in muscle fibers.







/article/94/10/4077/2597600 by guest on 03 O
ctober 2021
during the progression of T2D compared with healthy
lean heterozygous control rats. Higher protein levels of
OXPAT and ADRP were paralleled by higher IMCL levels
in ZDF rats. At 6 wk of age, however, when ZDF rats
were insulin-resistant but not diabetic yet, ADRP but
not OXPAT protein content was much higher in ZDF rats
compared with lean control rats, whereas IMCL levels
were only modestly higher in ZDF rats at this age. This
may indicate that high ADRP levels facilitate accumula-
tion of IMCL. Muscular OXPAT and ADRP protein con-
tent was not different between T2D patients and age- and
BMI-matched controls, which corresponds with similar
IMCL levels in both groups. Interestingly, in these pa-
tients, 8 wk of treatment with the insulin-sensitizer ros-
FIG. 4. A–D, OXPAT (A) and ADRP (C) content in muscle biopsies of T2D patients, before and after rosiglitazone treatment, and BMI-matched
control subjects. Individual values for OXPAT and ADRP in T2D patients before and after rosiglitazone treatment are shown in B and D,
respectively. #, P  0.05 in T2D patients before vs. after rosiglitazone treatment. E, IMCL content (expressed as area fraction) in muscle biopsies of
T2D patients, before and after rosiglitazone treatment, and BMI-matched control subjects. The IMCL content is shown for all muscle fibers, as well
as for type 1 and 2 fibers separately. No significant differences were present between T2D patients before rosiglitazone treatment and controls,
and no significant effect of rosiglitazone treatment was present.
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iglitazone [a peroxisome proliferator-activated receptor
(PPAR)- agonist] decreased both OXPAT and ADRP
protein content, without a (detectable) effect on IMCL
level. We conclude that OXPAT and ADRP are impli-
cated in myocellular lipid accumulation in humans and
rodents. Whether OXPAT and ADRP play a causal role
in the development of insulin resistance remains to be es-
tablished. Interestingly, muscle ADRP protein content
correlated negatively with insulin-stimulated glucose up-
take, suggesting that less ADRP is beneficial for insulin
sensitivity, consistent with the TZD-induced down-regu-
lation of ADRP/OXPAT. These data may therefore indi-
cate that ADRP and OXPAT are early markers of changes
in triacylglycerol accumulation and possibly of lipid in-
termediates in muscle.
Our results confirm the presence of OXPAT and ADRP
in human and rat skeletal muscle. ADRP was previously
shown to be expressed in skeletal muscle at both the
mRNA (14, 15) and protein (16, 17) level. Moreover,
ADRP was shown to be associated with im lipid droplets
(17). OXPAT expression (both mRNA and protein) was
also demonstrated in skeletal muscle (11, 21, 22). In iso-
lated cardiomyocytes, OXPAT and ADRP staining re-
vealed a punctate staining pattern with “dots” lying along
the muscle fiber, a pattern typically seen for lipid droplets
in muscle tissue. Our data (Figs. 1 and 3) also show that
OXPAT and ADRP stains overlap with the lipid staining,
demonstrating that both proteins are associated with lipid
droplets in human and rat skeletal muscle. From in vitro
experiments using multiple cell lines, it is known that
OXPAT resides within the cytoplasm in the absence of
neutral lipids and moves to the lipid droplet in conditions
that promote lipid droplet formation (11, 21). ADRP is
degraded by the proteasome if not bound to neutral lipids
(28, 29). Our stainings reveal intense punctate, lipid drop-
let-like staining of OXPAT. Expression of OXPAT on
other cytoplasmic sites was less obvious, but might have
been overwhelmed by the intense staining associated with
the lipid droplet. Our data extend previous data on the
muscle expression of OXPAT and ADRP by showing a
fiber type-specific expression pattern, with higher levels in
fibers that have a higher capacity for lipid storage.
At the age of 12 and 19 wk, when overt diabetes is
present in the ZDF rats, both OXPAT and ADRP protein
content are much higher than in lean control rats. This
matches with the largely increased IMCL content in the
tibialis anterior muscle (measured in vivo using 1H-mag-
netic resonance spectroscopy) of these same rats (30), as
well as with the large increases in IMCL content in the
soleus muscle of ZDF rats (6, 31). Although IMCL levels
in the ZDF rats are very high at these stages of maturation,
the drop in IMCL observed from 12 to 19 wk of age is
present for OXPAT only, and not for ADRP. At 6 wk,
when ZDF rats are in a prediabetic stage (hyperinsuline-
mic but still normoglycemic), IMCL content in tibialis an-
terior muscle was slightly higher than in lean controls (30).
We show that ADRP, but not OXPAT, is already highly
up-regulated at this stage, suggesting that an increased
amount of ADRP facilitates the accumulation of lipids.
This is supported by data showing that overexpression of
ADRP increases long-chain fatty acid uptake (32) and
lipid accumulation in several cell types (19, 20). More-
over, down-regulation of ADRP protein in the mouse liver
prevented lipid accumulation caused by a high-fat diet or
leptin deficiency (33, 34).
We show here that OXPAT and ADRP protein content
in skeletal muscle of T2D patients is similar to BMI-
matched control subjects, which is in line with similar
IMCL levels in both groups (Fig. 4). Our observation of
similar baseline levels of OXPAT and ADRP in T2D- and
BMI-matched control subjects might have been biased by
the use of lipid-lowering drugs, which was higher in the
T2D patients. Analysis of baseline OXPAT and ADRP
levels in subjects with and without lipid-lowering medi-
cation did, however, not hint toward consistently higher
or lower content of these proteins in subjects taking lipid-
lowering medication. Surprisingly, 8 wk of rosiglitazone
treatment did decrease both OXPAT and ADRP protein
content in skeletal muscle of T2D patients, without af-
fecting IMCL content. It has been shown before that ros-
iglitazone treatment in humans does not alter IMCL con-
tent (35, 36). PPAR and - regulate OXPAT and ADRP
protein expression in a tissue-specific manner. In mouse
skeletal muscle, PPAR is involved in the regulation of
OXPAT and ADRP expression (11, 21). Here we show
that the PPAR agonist rosiglitazone does not stimulate
ADRP and OXPAT expression in human muscle. Rather,
we observe declined OXPAT and ADRP levels. The
FIG. 5. Muscular ADRP protein content correlates negatively with
insulin-stimulated glucose uptake in a combined group of untreated
T2D patients before rosiglitazone treatment and healthy, BMI-matched
controls (r 0.50, P 0.017).
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present study is the first to present data on myocellular
OXPAT protein levels in human skeletal muscle of T2D
patients. Previous work in humans on OXPAT in muscle
was at the level of gene expression and revealed no change
in OXPAT gene expression in impaired glucose-tolerant
subjects taking pioglitazone for 10 wk (a PPAR agonist
with PPAR affinity) (11). Comparing the data set in the
present study with the data shown in the paper by Wolins
et al. (11) is complicated; first and for all, the present study
shows data on protein rather than mRNA level. Further-
more, the study by Wolins et al. (11) was performed in a
group of impaired glucose-tolerant subjects of unknown
gender, age, and BMI. These subjects were selected from
a larger population of mixed gender (69 females, 16
males), with wide variety in age (21–66 yr) and BMI
(20–55 kg/m2), and hence it is not unlikely that the sub-
group that received pioglitazone was heterogeneous as
well regarding gender, age, and BMI, all factors likely to
affect myocellular lipid metabolism and insulin sensitivity.
Our finding of decreased muscle OXPAT and ADRP ex-
pression is also interesting in light of the improved insulin
sensitivity caused by rosiglitazone treatment. A putative
explanation for this may be that the decline in OXPAT and
ADRP facilitates a decline in recognized insulin-desensi-
tizing intermediates like diacylglycerol within the lipid
droplet. Because both diacylglycerol and triacylglycerol
are stained by ORO, interconversion will not be reflected
in stainings or in 1H-magnetic resonance spectroscopy-
based IMCL analyses. Based on the putative functions of
both proteins in the efficient storage of intracellular lipids
and the regulation of lipases acting on the lipid droplets,
an increase, rather than a decrease, in their expression
would be expected after an insulin-sensitizing intervention
(9, 37). Indeed, Phillips et al. (16) showed an increase of
both muscle ADRP protein and insulin sensitivity in obese
nondiabetic subjects after a weight-loss intervention and
in obese T2D patients after pharmacological intervention
(metformin or troglitazone). Our finding of a negative
correlation between insulin-stimulated glucose uptake
and ADRP content (Fig. 5) is in contrast with these latter
findings (16) and suggests that low rather than high
OXPAT and ADRP content would help to improve in-
sulin sensitivity.
In conclusion, our data support a role for OXPAT and
ADRP in muscular lipid accumulation. OXPAT and
ADRP protein is expressed in human and rat skeletal mus-
cle in a fiber type-specific manner, with higher amounts in
fibers that have a higher capacity to store lipids. More-
over, muscle OXPAT and ADRP protein are highly in-
creased in parallel with IMCL content in ZDF rats that
progress to insulin resistance. Consistently, in humans no
differences in muscle OXPAT and ADRP content were
observed between T2D patients and BMI-matched con-
trols that have a similar IMCL content, whereas ADRP
expression was inversely related to insulin sensitivity. In
contrast, rosiglitazone treatment decreased skeletal mus-
cle OXPAT and ADRP protein content without affecting
IMCL content, while improving insulin sensitivity. These
data show that in human skeletal muscle, OXPAT and
ADRP are not responsive to the PPAR agonist rosiglita-
zone in the dosage and duration used. Moreover, our data
do not support the hypothesis that an improvement in
insulin sensitivity depends on increased levels of PAT pro-
teins that act by improving the efficiency of lipid storage
and lipolytic control.
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